Buscar en
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Toda la web
Inicio Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) Clinical behaviour of papillary thyroid cancer oncocytic variant: stage-matched ...
Journal Information
Vol. 42. Issue 2.
Pages 100-105 (March - April 2023)
Share
Share
Download PDF
More article options
Vol. 42. Issue 2.
Pages 100-105 (March - April 2023)
Original Article
Clinical behaviour of papillary thyroid cancer oncocytic variant: stage-matched comparison versus classical and tall cell variant papillary thyroid cancer
Comportamiento clínico de la variante oncocítica del cáncer papilar de tiroides: Comparación de su evolución frente al cáncer papilar variantes clásica y de células altas
K. Okuyucua, S. Incea,
Corresponding author
drsemra@gmail.com

Corresponding author.
, A. Cinara, H. Sana, M. Samsuma, N. Dizdara, E. Alagoza, I. Demircib, M. Ozkarac, B. Gunalpa, A.O. Karaçalıoglua
a University of Health Sciences, Gulhane Training and Research Hospital, Nuclear Medicine Department, Ankara, Turkey
b University of Health Sciences, Gulhane Training and Research Hospital, Endocrinology Department, Ankara, Turkey
c University of Health Sciences, Gulhane Training and Research Hospital, General Surgery Department, Ankara, Turkey
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Tables (4)
Table 1. Mean values and the statistical comparison of oncocytic variant versus classical variant of thyroid papillary carcinoma according to some basic predictor variables.
Table 2. Mean values and the statistical comparison of oncocytic variant versus tall cell variant of thyroid papillary carcinoma according to some basic predictor variables.
Table 3. The stage-matched comparison of recurrence rates between oncocytic and classical variants of thyroid papillary carcinoma.
Table 4. The stage-matched comparison of recurrence rates between oncocytic and tall cell variants of thyroid papillary carcinoma.
Show moreShow less
Abstract
Objective

Papillary thyroid cancer (PTC) has many variants and most of them are mild tumors. Oncocytic variant (OV) is a rare subtype of PTC. There are controversial results about its prognosis in the literature. We investigated its aggressivity and clinical course by comparing it with classical variant (CV) and tall cell variant (TV) of PTC over a stage-matched design.

Material and Methods

Pure 100 OV, 71TV and 1219 CV were included in this retrospective cohort study. OV was compared with CV and TV according to independent prognostic parameters. OV was also compared stage by stage with CV and TV for recurrence.

Results

Mean age was 46,8 years and male/female ratio 25/75 for OV. The recurrence rates in our study were 16% in OV, 13,5% in CV and 56% in TV. There is a statistically significant difference according to recurrence between stage I and stage IV OV and CV (p=0.023, p=0.03, respectively). There is also a statistically significant difference between stage I and stage IV OV and TV according to recurrence (p=0.001, p=0.024, respectively). OV can be supposed to behave between CV and TV, but very closer to CV.

Conclusions

OV seems to be slightly more aggressive than CV. Despite an inadequate sample size for stage II and III, our findings imply an increased recurrence risk for OV than CV at the advanced stages (stage III and IV) and CV has an unfavorable prognosis than OV at early stages (stage I and II) according to stage-matched model.

Keywords:
Papillary thyroid cancer
Oncocytic variant
Classical variant
Tall cell variant
Resumen
Objetivo

El cáncer papilar de tiroides (CPT) tiene diferentes variantes y la mayoría de ellas presentan diferencias sutiles. La variante oncocítica (VO) es un subtipo poco frecuente de CPT y en la literatura existen resultados controvertidos sobre el pronóstico de esta variante. Investigamos su agresividad y curso clínico comparándolo con la variante clásica (VC) y la variante de células altas (CA) de CPT en diferentes estadios.

Material y métodos

En este estudio de cohortes retrospectivo se incluyeron: 100 muestras simples de VO, 71 de CA y 1219 de VC. Las muestras VO se compararon con las VC y las de CA sobre la base de parámetros de pronóstico independientes. La recurrencia de la VO también se comparó estadio por estadio con la VC y CA.

Resultados

La edad media fue de 46,8 años y la relación hombres/mujeres 25/75 para la VO. Las tasas de recurrencia en nuestro estudio fueron de 16% en VO, 13,5% en VC y 56% en CA. Existe una diferencia estadísticamente significativa con respecto a la recurrencia entre el estadio I y el estadio IV comparando la VO y la VC (p=0,023, p=0,03, respectivamente). También hay una diferencia estadísticamente significativa con respecto a la recurrencia entre el estadio I y el estadio IV comparando la VO y la CA (p=0,001; p=0,024, respectivamente). Se puede suponer que la VO tiene un comportamiento entre la VC y la CA, pero muy cercana a la CA.

Conclusión

La VO parece ser un poco más agresiva que la VC. A pesar de un tamaño de muestra inadecuado para el estadio II y III, nuestros hallazgos implican un mayor riesgo de recurrencia para la VO que la VC en los estadios avanzados (estadios III y IV) y la VC tiene un pronóstico desfavorable que VO en estadios precoces (estadios I y II) según el modelo de estadio pareado.

Palabras clave:
Cáncer de tiroides papilar
Variante oncocítica
Variante clásica
Variante de células altas

Article

These are the options to access the full texts of the publication Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.remnie.2024.02.001
No mostrar más